A fundamental problem in healthcare R&D is that the development of new products is very expensive: failures and delays are frequent and each one is costly. In fact, the number of new drugs approved per billion US dollars spent on R&D has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms (1). In addition, finding the right pricing and reimbursement strategy has become increasingly difficult on a global level. Bottomline: not every launch is as successful as it could be if there is no overarching product strategy.
If you are still looking for the optimal strategy for your product or portfolio or simply want your project to get back on track, ProDeMaCon LLC can provide strategic and executional advice, given its unique setup:
(1) J.W. Scannell et al., Nature Reviews Drug Discovery 11, 191-200 (March 2012)
ProDeMaCon: Product Development and Marketing Consulting, LLC
© 2021 ProDeMaCon LLC - All Rights Reserved.